Comparison of the Efficacy of Brolucizumab with Natural Disease Progression in Wet AMD Using Clinical Data from the Phase III HAWK and HARRIER Trials and Modelled Placebo Data

References

• Schmidt-Erfurth U, Chong V, Loewenstein A, Larsen M, Souied E, Schlingemann R, Eldem B, Monés J, Richard G, Bandello F; European Society of Retina Specialists. Guidelines for the management of neovascular age-related macular degeneration by the European society of retina specialists (EURETINA). Br J Ophthalmol. 2014;98(9):1144–67. doi:10.1136/bjophthalmol-2014-305702.
   PubMed Web of Science ®Google Scholar
• Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng CY, Wong TY. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):e106–16. doi:10.1016/S2214-109X(13)70145-1.
   PubMed Web of Science ®Google Scholar
• Yonekawa Y, Miller JW, Kim IK. Age-related macular degeneration: advances in management and diagnosis. J Clin Med. 2015;4(2):343–59. doi:10.3390/jcm4020343.
   PubMed Web of Science ®Google Scholar
• Ferris FL, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol. 1984;102:1640–42. doi:10.1001/archopht.1984.01040031330019.
   PubMed Web of Science ®Google Scholar
• Ladas ID, Chatziralli IP, Kotsolis AI, Douvali M, Georgalas I, Theodossiadis PG, Rouvas AA. Intravitreal ranibizumab versus thermal laser photocoagulation in the treatment of extrafoveal classic choroidal neovascularization secondary to age-related macular degeneration. Ophthalmologica. 2012;228(2):93–101. doi:10.1159/000337347.
   PubMed Web of Science ®Google Scholar
• Kent C. Rev Ophthalmol; 2009 [accessed 2019 Dec]. https://www.reviewofophthalmology.com/article/macular-degeneration-is-laser-still-relevant.
   Google Scholar
• Bressler NM, Arnold J, Benchaboune M, Blumenkranz MS, Fish GE, Gragoudas ES, Lewis H, Schmidt-Erfurth U, Slakter JS, Bressler SB, et al. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition’s impact on vision outcomes-TAP report No. 3. Arch Ophthalmol. 2002;120(11):1443–54.
   PubMedGoogle Scholar
• Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432–44. doi:10.1056/NEJMoa062655.
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419–31. doi:10.1056/NEJMoa054481.
   PubMed Web of Science ®Google Scholar
• Campbell JP, Bressler SB, Bressler NM. Impact of availability of anti-vascular endothelial growth factor therapy on visual impairment and blindness due to neovascular age-related macular degeneration. Arch Ophthalmol. 2012;130(6):794–95. doi:10.1001/archophthalmol.2011.2480.
   PubMedGoogle Scholar
• Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, Kirchhof B, Ho A, Ogura Y, Yancopoulos GD, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012 Dec;119(12):2537–48. doi:10.1016/j.ophtha.2012.09.006.
   PubMed Web of Science ®Google Scholar
• Tietz J, Spohn G, Schmid G, Konrad J, Jampen S, Maurer P, Schmidt A, Escher D. Affinity and potency of RTH258 (ESBA1008), a novel inhibitor of vascular endothelial growth factor a for the treatment of retinal disorders. Invest Ophthalmol Vis Sci. 2015;56. [abstract 1501].
   Web of Science ®Google Scholar
• Escher D, Schmidt A, Steiner P, Maurer P, Weissgerber G. Single-chain antibody fragments in ophthalmology. Presented at the European Society of Retina Specialists 15th EURETINA Congress; 2015 Sep 17–20; Nice, France. http://abstracts.euretina.org/.
   Google Scholar
• Nimz EL, Van’t Land CW, Yáñez JA, Chastain JE. Intraocular and systemic pharmacokinetics of brolucizumab (RTH258) in nonhuman primates. Invest Ophthalmol Vis Sci. 2016;57(12):4996.
   Google Scholar
• Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, Brown DM, Gomes AV, Warburton J, Weichselberger A, Holz FG; HAWK and HARRIER Study Investigators. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2019; pii: S0161-6420(18)33018–5. doi:10.1016/j.ophtha.2019.04.017. [Epub ahead of print].
   Web of Science ®Google Scholar
• Dugel PU, Jaffe G, Schmidt-Erfurth U, Ogura Y, Koh A, Weissgerber G, Weichselberger A, Holz FG. Brolucizumab for neovascular AMD: the 2-Year HAWK and HARRIER results. Presented at the American Academy of Ophthalmology 122nd Annual Meeting; 2018 Oct 27–30; Chicago, USA. http://www.aao.org/annualmeeting/education/retina.
   Google Scholar
• Mulyukov Z, Weber S, Pigeolet E, Clemens A, Lehr T, Racine A. Neovascular age-related macular degeneration: a visual acuity model of natural disease progression and ranibizumab treatment effect. CPT Pharmacometrics Syst Pharmacol. 2018;7(10):660–69. doi:10.1002/psp4.2018.7.issue-10.
   PubMedGoogle Scholar
• Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S, Shams N. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1. Am J Ophthalmol. 2008;145(2):239–48. doi:10.1016/j.ajo.2007.10.004.
   PubMed Web of Science ®Google Scholar
• Schmidt-Erfurth U, Eldem B, Guymer R, Korobelnik JF, Schlingemann RO, Axer-Siegel R, Wiedemann P, Simader C, Gekkieva M, Weichselberger A; EXCITE Study Group. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology. 2011;118(5):831–39. doi:10.1016/j.ophtha.2010.09.004.
   PubMed Web of Science ®Google Scholar
• Busbee BG, Ho AC, Brown DM, Heier JS, Suñer IJ, Li Z, Rubio RG, Lai P; HARBOR Study Group. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2013;120(5):1046–56. doi:10.1016/j.ophtha.2012.10.014.
   PubMed Web of Science ®Google Scholar
• International council of ophthalmology: visual standards aspects and ranges of vision loss with emphasis on population surveys. [ accessed 2019 Dec]. http://www.icoph.org/downloads/visualstandardsreport.pdf.
   Google Scholar
• Holz FG, Korobelnik JF, Lanzetta P, Mitchell P, Schmidt-Erfurth U, Wolf S, Markabi S, Schmidli H, Weichselberger A. The effects of a flexible visual acuity-driven ranibizumab treatment regimen in age-related macular degeneration: outcomes of a drug and disease model. Invest Ophthalmol Vis Sci. 2010;51(1):405–12. doi:10.1167/iovs.09-3813.
   PubMed Web of Science ®Google Scholar